Masking MALT1: the paracaspase's potential for cancer therapy

A key feature of aggressive B cell lymphomas is constitutive NF-κB activation, which requires signals from the CARD11–BCL-10–MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the NF-κB inhibitor A20. New data shows that targeting MAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Vucic, Domagoj, Dixit, Vishva M.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2009
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768848/
https://www.ncbi.nlm.nih.gov/pubmed/19841088
http://dx.doi.org/10.1084/jem.20092160
Descripción
Sumario:A key feature of aggressive B cell lymphomas is constitutive NF-κB activation, which requires signals from the CARD11–BCL-10–MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the NF-κB inhibitor A20. New data shows that targeting MALT1 protease activity may be a promising therapeutic strategy for treating aggressive B cell lymphomas.

Ejemplares similares